ERBB2 and cancer: Nine (75.0%) of the 12 cancers with the −815A>T variant were ER+ and ERBB2− (the remaining three were ER–/ERBB2–) as compared with 553 (63.2%) out of the 874 cancers that did not harbor −815A>T (P = 0.551).